New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
06:03 EDTPAA, FIATY, JPM, F, BRK.A, RBS, GMOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Will this finally be the year that investors dump bonds and return to stocks? Some signs are indicating that maybe, possibly, the tide is beginning to reverse. For the week ended Wednesday, U.S. investors plowed $18B into stock mutual funds and exchange-traded funds, the largest one-week total since June 2008, the Wall Street Journal reports...Auto makers (GM, F, FIATY) have found a quicker path to improved fuel efficiency, reinventing the way traditional gas-powered cars are built. They’re cutting weight by substituting more plastics, aluminum and magnesium, including materials once found only in high-end race cars, the Wall Street Journal reports...REUTERS: The U.S. economy is expected to grow by 2.5% in 2013, improving to 3.5% growth in 2014, said Chicago Fed President Charles Evans. He also forecast the U.S. unemployment rate would be 7.4% this year, easing to about 7% in 2014, Reuters reports...CVC Capital Partners and Royal Bank of Scotland (RBS) sold a combined $290M stake in Hong Kong-listed luggage maker Samsonite International, according to a term sheet, Reuters reports...BLOOMBERG: JPMorgan Chase’s (JPM) board will consider releasing an internal report this week that faults CEO Jamie Dimon’s oversight of a division that lost more than $6.2B on botched trades, sources say, Bloomberg reports...A group of oil and gas pipeline operators led by Plains All American Pipeline LP (PAA) announced plans just in the past three months to spend about $1B on rail depot projects to help move more crude from inland fields to refineries on the coasts.Warren Buffett’s (BRK.A) Burlington Northern Santa Fe LLC, the largest U.S. railroad, spent $400M on terminals in 2012, Bloomberg reports
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
18:31 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for OPDIVO
Subscribe for More Information
15:23 EDTADako announces FDA approval of new lung test for cancer patients
Subscribe for More Information
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use